• Loading stock data…

FDA

INVESTOR ALERT: Why Amarin May Already Know Their Chances of Receiving Priority Review

Amarin (AMRN) submitted its supplemental new drug application (sNDA) for Vascepa on March 28th. Given the FDA review timeline, there are upcoming catalysts for this filing that could weigh heavily on … [Read more...] about INVESTOR ALERT: Why Amarin May Already Know Their Chances of Receiving Priority Review

Shorts Fighting To Keep CPRX from Gaining Momentum-Insiders Aren’t Phased

After a little research it appears that shorts are working overtime to hold Catalyst Pharmaceuticals (Nasdaq: CPRX) under $3.0. Only 5 days ago we were at $3.20. A month ago and before the PDUFA date … [Read more...] about Shorts Fighting To Keep CPRX from Gaining Momentum-Insiders Aren’t Phased

GALT is Primed for Acquisition or Partnership

Overview Galectin Therapeutics (NASDAQ GALT $5.96) is a leader in the development of a treatment for  Non-Alcoholic SteatoHepatitis, an unmet medical need worth billions. Their star drug … [Read more...] about GALT is Primed for Acquisition or Partnership